Shares of the maker of medicine to treat autoimmune and inflammatory diseases rose after announcing plans to take its popular Acthar rheumatoid arthritis medicine into new markets. The FDA has already approved Acthar for 19 uses, including multiple sclerosis. Questcor Pharmaceuticals (QCOR) plans to market the drug to treat the inflammation diseases polymyositis (PM) and dermatomyositis (DM). The move is seen generating significant new revenue. Questcor shares rose 4.9% to 48.69.